WASHINGTON — Medicaid advocates have a lot of opinions about the Trump administration’s rebate rule. Namely, that it makes no sense.

The Trump administration’s controversial proposal to eliminate the drug rebates that pharmacy middlemen and insurers use to negotiate down the price of certain drugs doesn’t stop with that massive change — it proposes eliminating some of the rebates in Medicaid, too. The administration argues that in both programs, the policy will force pharmacies to pass rebates directly to the consumer, meaning lower prices at the pharmacy counter.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy